The FDA wants to make drug development more efficient and effective by modernizing how the agency collects and evaluates clinical information, allowing adaptive clinical trial designs and master protocols, and communicating more with clinical trial sponsors, investigators, review boards and other stakeholders, Commissioner Scott Gottlieb said.
FDA commissioner outlines plan for lowering drug-development costs
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.